GNI Group Ltd. (JP:2160)
:2160
Want to see JP:2160 full AI Analyst Report?
2160 Stock Chart & Stats
¥3370.00
¥50.00(1.64%)
At close: 4:00 PM EST
¥3370.00
¥50.00(1.64%)
Day’s Range― - ―
52-Week Range¥2,112.00 - ¥4,410.00
Previous CloseN/A
Volume492.20K
Average Volume (3M)969.16K
Market Cap
¥164.79B
Enterprise Value¥148.81B
Total Cash (Recent Filing)¥21.10B
Total Debt (Recent Filing)¥5.37B
Price to Earnings (P/E)26.0
Beta1.16
Next Earnings
Aug 17, 2026EPS Estimate
-2.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-85.07
Shares Outstanding55,767,544
10 Day Avg. Volume1,104,200
30 Day Avg. Volume969,156
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,800.00Price Target Upside12.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)53.4
Revenue Forecast (FY)¥30.85B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet With Low LeverageA low debt-to-equity (~0.13) and material equity growth provide durable financial resilience. This balance sheet strength gives management flexibility to fund R&D, pursue licensing or M&A, and withstand clinical or commercialization setbacks without immediate liquidity pressure.
High Gross Margins And Multi-year Revenue Growth TrendSustained multi-year revenue growth coupled with very high gross margins indicates strong product economics and pricing power. These fundamentals support eventual margin recovery at the operating level and allow reinvestment into R&D and commercialization when cost trajectories normalize.
Diversified Biopharma Business Model And PipelineA diversified model—drug development, manufacturing, commercialization, and licensing—reduces single-product dependency. A robust pipeline focused on respiratory and fibrotic diseases and active partnerships increase long-term upside from clinical successes and recurring licensing or royalty streams.
Bears Say
Two Consecutive Years Of Negative Operating And Free Cash FlowSustained cash burn undermines self-funding ability and raises execution risk for development programs. Continued negative OCF/F CF makes the company reliant on external financing, which can dilute shareholders or constrain R&D and commercialization timing if capital markets are less accessible.
Sharp Deterioration To Operating And Net Losses In 2025A material swing to operating and net losses reduces internal reinvestment capacity and heightens funding needs. Persistent losses can delay commercialization milestones, weaken negotiating power for partnerships, and increase sensitivity to external financing costs and investor scrutiny.
Volatile Revenue And Earnings History Reduces VisibilityInconsistent revenue and steep EPS decline reflect earnings volatility and execution risk. Such variability complicates forecasting, undermines confidence in sustainable margin improvement, and increases the probability that future results hinge on a small number of trial or commercial outcomes.
GNI Group News
2160 FAQ
What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was ¥2112.00 and its highest was ¥4410.00 in the past 12 months.
What is GNI Group Ltd.’s market cap?
GNI Group Ltd.’s market cap is ¥164.79B.
When is GNI Group Ltd.’s upcoming earnings report date?
GNI Group Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 92 days.
How were GNI Group Ltd.’s earnings last quarter?
GNI Group Ltd. released its earnings results on May 15, 2026. The company reported -¥38.2 earnings per share for the quarter, missing the consensus estimate of -¥2.74 by -¥35.46.
Is GNI Group Ltd. overvalued?
According to Wall Street analysts GNI Group Ltd.’s price is currently Undervalued.
Does GNI Group Ltd. pay dividends?
GNI Group Ltd. does not currently pay dividends.
What is GNI Group Ltd.’s EPS estimate?
GNI Group Ltd.’s EPS estimate is -2.63.
How many shares outstanding does GNI Group Ltd. have?
GNI Group Ltd. has 55,767,544 shares outstanding.
What happened to GNI Group Ltd.’s price movement after its last earnings report?
GNI Group Ltd. reported an EPS of -¥38.2 in its last earnings report, missing expectations of -¥2.74. Following the earnings report the stock price went down -1.99%.
Which hedge fund is a major shareholder of GNI Group Ltd.?
Currently, no hedge funds are holding shares in JP:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GNI Group Ltd.
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
2160 Stock 12 Month Forecast
Average Price Target
¥3,800.00
▲(12.76% Upside)
Technical Analysis
Peptidream
―
SanBio Co
―
Sosei Group
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
Options Prices
Currently, No data available
---